Endocrine Society TRT Guideline
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (Bhasin et al., JCEM 2018)
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
0 human trials, about 200 studies, Systematic evidence synthesis (not a single cohort). The written rationale for this grade is still being prepared.
- FDA
- Professional society guideline synthesizing approved-therapy evidence
Reference only. Not medical advice.
What can go wrong
The guideline's protective function is to prevent over-diagnosis and unmonitored prescribing: it warns against treating non-specific aging symptoms, mandates hematocrit and PSA monitoring, and excludes high-risk men - precisely the safeguards often skipped in direct-to-consumer testosterone settings.
This is something to take to a clinician. The Atlas can tell you what is known about endocrine society trt guideline in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The 2018 Endocrine Society Clinical Practice Guideline, led by Shalender Bhasin, is the authoritative GRADE-based synthesis of how to diagnose and treat male hypogonadism. It recommends diagnosing hypogonadism only in men with BOTH consistent symptoms AND unequivocally low morning testosterone confirmed on repeat testing, treating to mid-normal levels, and explicitly avoiding testosterone in men with certain cardiovascular and prostate conditions or those seeking fertility. As an evidence-synthesis dossier it codifies the lessons of EMAS, the T-Trials, and the cardiovascular debate into conservative, accountable practice.
The reference framework that turns testosterone evidence into prescribing discipline.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Confirmed symptomatic hypogonadism
- Recommends TRT only when low morning T is confirmed on two measurements alongside consistent symptoms
- Monitoring
- Specifies follow-up of testosterone, hematocrit, and PSA, with thresholds for action
- Contraindications
- Advises against TRT in men with recent cardiovascular events, untreated prostate/breast cancer, or fertility goals
How it works
The guideline aggregates randomized and observational evidence using the GRADE system, weighting study quality, to produce graded recommendations - distinguishing strong recommendations backed by good evidence from weaker, lower-certainty suggestions.
What a guideline can and cannot do
A guideline is a synthesis, not new data, and is only as strong as the trials beneath it - in 2018 the cardiovascular evidence was still uncertain (TRAVERSE had not reported). Many recommendations are conditional/weak by GRADE standards. It does not bind the cash-pay telehealth and 'optimization' marketplace, which frequently diagnoses on single lab values and treats non-specific symptoms the guideline explicitly cautions against.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
What it does to fertility
The guideline explicitly recommends against exogenous testosterone in men desiring fertility, because it suppresses the hypothalamic-pituitary-gonadal axis and impairs spermatogenesis; it directs such men to alternatives.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Serum testosterone (target mid-normal range)
- Hematocrit (hold/reduce if >54%)
- Prostate-specific antigen (PSA)
- Symptom response
- Blood pressure
What people get wrong
Often saidAny man with a below-range testosterone result should start TRT
ActuallyThe guideline requires consistent symptoms PLUS low morning testosterone confirmed on a repeat sample, and advises against treating non-specific aging symptoms - directly contradicting single-lab-value prescribing.
Often saidTRT is appropriate for men trying to conceive
ActuallyThe guideline explicitly advises against testosterone in men seeking fertility because it suppresses sperm production.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
The Endocrine Society has issued successive testosterone guidelines (2006, 2010, 2018). The 2018 Bhasin-led revision is the most rigorous, built on GRADE methodology and informed by EMAS and the T-Trials. It remains the principal professional reference and the standard against which commercial prescribing patterns are measured.
- 2006First Endocrine Society testosterone guideline
- 2010Updated guideline
- 2018Bhasin-led GRADE-based revision published in JCEM
- 2023TRAVERSE later supplies the cardiovascular data the 2018 guideline lacked
What the trials could not show
Limits of the studies themselves, as distinct from limits of the treatment.
- Pre-dates TRAVERSE, so its cardiovascular guidance reflects 2018 uncertainty; many recommendations are conditional/low-certainty under GRADE; guidelines lag new evidence and are not self-enforcing; some thresholds remain debated; reflects U.S./Endocrine Society perspective.
What we do not know
- How should the post-TRAVERSE cardiovascular signals revise future guidance?
- How can guideline standards be extended to the cash-pay telehealth market?
At a glance
- Type
- GRADE-based clinical practice guideline
- Lead author
- Shalender Bhasin
- Publisher
- Journal of Clinical Endocrinology & Metabolism, 2018
- Diagnosis rule
- Symptoms PLUS low morning total T confirmed on a repeat sample
- Treatment target
- Mid-normal serum testosterone range
- Key exclusions
- Recent MI/stroke, untreated prostate/breast cancer, desire for fertility, elevated hematocrit, severe untreated sleep apnea
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Endocrine Society TRT Guideline. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Bhasin et al. Endocrine Society Guideline (JCEM)2018
Codified symptom-plus-confirmed-biochemistry diagnosis, mid-normal treatment target, structured monitoring of hematocrit and PSA, and clear exclusions; recommended against routine testosterone for non-specific aging symptoms
Guideline integration of EMAS and the T-Trials2018
Adopted EMAS-style syndromic diagnosis and the T-Trials' domain-specific efficacy evidence, while cautioning on cardiovascular uncertainty pending TRAVERSE